Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Cell therapies, most notably CAR T-cell therapies, have had an important impact on the field of hematology, Ramakrishnan says. Most recently, the field has seen pivotal research with CAR T cells in the second-line setting for DLBCL, Ramakrishnan adds.

The phase 3 ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials led to the FDA approvals of axicabtagene ciloleucel (axi-cel; Yescarta) and lisocabtagene maraleucel (liso-cel; Breyanzi) in the second-line setting of DLBCL, Ramakrishnan explains.

Overall, as more treatment options, it is important to consider become available how to sequence these treatments for patients, Ramakrishnan concludes.

Videos

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma (LBCL).

After little progress was made in the treatment of diffuse large B-cell lymphoma for about a decade, the previous few years have presented key developments in the space, Ramakrishnan says. Novel biology-based strategies and advancements in cell therapies have given patients with LBCL a second opportunity to receive effective treatment, Ramakrishnan explains.

Although CAR T-cell therapy has shifted the needle in LBCL, more work needs to be done, Ramakrishnan continues. Additional research into CAR T-cell therapy in the future will further assist in understanding the biology of LBCL and how to best sequence therapies for patients, Ramakrishnan concludes.

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.


Praveen Ramakrishnan, MD, MS

Articles

Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL